PMC:7243768 / 52585-52727 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2020","span":{"begin":46,"end":54},"obj":"Species"},{"id":"2031","span":{"begin":25,"end":31},"obj":"Disease"},{"id":"2032","span":{"begin":65,"end":73},"obj":"Disease"}],"attributes":[{"id":"A2020","pred":"tao:has_database_id","subj":"2020","obj":"Tax:9606"},{"id":"A2031","pred":"tao:has_database_id","subj":"2031","obj":"MESH:D009369"},{"id":"A2032","pred":"tao:has_database_id","subj":"2032","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" presented with IV stage cancer. 28.6% of the patients developed COVID-19 while receiving antitumor therapy, whereas 71.4% of them developed d"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T601","span":{"begin":25,"end":31},"obj":"Disease"},{"id":"T602","span":{"begin":65,"end":73},"obj":"Disease"}],"attributes":[{"id":"A601","pred":"mondo_id","subj":"T601","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A602","pred":"mondo_id","subj":"T602","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" presented with IV stage cancer. 28.6% of the patients developed COVID-19 while receiving antitumor therapy, whereas 71.4% of them developed d"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T11215","span":{"begin":16,"end":18},"obj":"Chemical"}],"attributes":[{"id":"A84912","pred":"chebi_id","subj":"T11215","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"}],"text":" presented with IV stage cancer. 28.6% of the patients developed COVID-19 while receiving antitumor therapy, whereas 71.4% of them developed d"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T250","span":{"begin":25,"end":31},"obj":"Phenotype"}],"attributes":[{"id":"A250","pred":"hp_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":" presented with IV stage cancer. 28.6% of the patients developed COVID-19 while receiving antitumor therapy, whereas 71.4% of them developed d"}